Literature DB >> 12893416

Oxidative stimuli affect polyglutamine aggregation and cell death in human mutant ataxin-1-expressing cells.

Sung-Jo Kim1, Tae-soo Kim, Sunghoi Hong, Hyangshuk Rhim, Ick Young Kim, Seongman Kang.   

Abstract

Spinocerebellar ataxia 1 (SCA1), one of the inherited polyglutamine neurodegenerative diseases, is associated with intracellular aggregates. However, the process of aggregate formation and the factors that influence aggregation remain unclear. Here, we show that oxidative stimuli and alteration of the cellular redox state significantly affect aggregation and cell death in cells expressing mutant ataxin-1, the SCA gene product. Treatment of cells with buthionine sulfoximine, hydrogen peroxide or t-butylhydroperoxide increased the formation of mutant ataxin-1 aggregates, but treatment with the anti-oxidant, N-acetylcysteine (NAC), decreased aggregate formation. Oxidative damage of mutant ataxin-1 protein increased its recruitment in nuclear aggregates and increased cell death. However, NAC treatments reduced cell death and the number of cells with abnormal morphology. Our results might give insight into the mechanism whereby polyglutamine proteins aggregate and suggest that treatment of appropriate antioxidant reagents might prevent progression of SCA1 and other polyglutamine diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893416     DOI: 10.1016/s0304-3940(03)00657-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration.

Authors:  S M Hearst; L R Walker; Q Shao; M Lopez; D Raucher; P J S Vig
Journal:  Neuroscience       Date:  2011-09-17       Impact factor: 3.590

Review 2.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

3.  Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status.

Authors:  Gülin Oz; Diane Hutter; Ivan Tkác; H Brent Clark; Myron D Gross; Hong Jiang; Lynn E Eberly; Khalaf O Bushara; Christopher M Gomez
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

4.  Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model.

Authors:  Abiodun Ajayi; Xin Yu; Staffan Lindberg; Ulo Langel; Anna-Lena Ström
Journal:  BMC Neurosci       Date:  2012-07-24       Impact factor: 3.288

Review 5.  RORalpha, a pivotal nuclear receptor for Purkinje neuron survival and differentiation: from development to ageing.

Authors:  Fatiha Boukhtouche; Mohamed Doulazmi; Florence Frederic; Isabelle Dusart; Bernard Brugg; Jean Mariani
Journal:  Cerebellum       Date:  2006       Impact factor: 3.648

Review 6.  Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.

Authors:  Melvin M Evers; Lodewijk J A Toonen; Willeke M C van Roon-Mom
Journal:  Mol Neurobiol       Date:  2013-11-29       Impact factor: 5.590

7.  Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models.

Authors:  Chiung-Mei Chen; Wan-Ling Chen; Chen-Ting Hung; Te-Hsien Lin; Ming-Chung Lee; I-Cheng Chen; Chih-Hsin Lin; Chih-Ying Chao; Yih-Ru Wu; Kuo-Hsuan Chang; Hsiu Mei Hsieh-Li; Guey-Jen Lee-Chen
Journal:  Aging (Albany NY)       Date:  2019-02-13       Impact factor: 5.682

Review 8.  Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review.

Authors:  Michael Weng Lok Phang; Sze Yuen Lew; Ivy Chung; William Kiong-Seng Lim; Lee Wei Lim; Kah Hui Wong
Journal:  Chin Med       Date:  2021-01-28       Impact factor: 5.455

Review 9.  Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies.

Authors:  Benjamin R Underwood; David C Rubinsztein
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.